Related Experiment Video
Updated: May 29, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Stability of hepatitis B surface antigen over time: implications for studies using stored sera
James Fung1, Ching-Lung Lai, John Young
1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
Hepatitis B surface antigen (HBsAg) levels in stored sera remain stable for up to 12 months. This stability confirms that quantitative HBsAg measurements in frozen samples are reliable for chronic hepatitis B disease management.
Area of Science:
- Hepatology
- Virology
- Clinical Chemistry
Background:
- Quantitative hepatitis B surface antigen (HBsAg) measurements are increasingly used in chronic hepatitis B management.
- The stability of HBsAg levels in stored sera is crucial for reliable disease monitoring but has not been well-established.
Purpose of the Study:
- To prospectively assess the stability of hepatitis B surface antigen (HBsAg) levels in frozen sera stored for one year.
Main Methods:
- 105 fresh serum samples were divided into five aliquots.
- One aliquot was tested at baseline; the others were stored at -20°C and tested at 3, 6, 9, and 12 months.
- HBsAg levels were measured using the Elecsys HBsAg II assay.
Main Results:
- HBsAg levels showed no significant overall difference across the 12-month storage period.
- High correlations were observed between consecutive time points (r > 0.987, P < 0.001).
- Over 99% of samples exhibited less than a 1-log change in HBsAg levels after 12 months.
Conclusions:
- Hepatitis B surface antigen (HBsAg) levels are stable in frozen sera for up to 12 months.
- Stored sera can be reliably used for accurate quantitative HBsAg measurements in chronic hepatitis B management.
More Related Videos
04:11Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022